Montelukast combined with intranasal mometasone furoate versus intranasal mometasone furoate; a comparative study in treatment of adenoid hypertrophy

Montelukast combined with intranasal mometasone furoate versus intranasal mometasone furoate; a comparative study in treatment of adenoid hypertrophy

To evaluate the role of combined therapy using montelukast and intranasal mometasone furoate compared to intranasal mometasone furoate alone in treatment of adenoid hypertrophy regarding efficacy and recurrence rate. The study included 100 children with adenoid hypertrophy, they were randomly assign...

Full description

Saved in:
Bibliographic Details
Published in:American journal of otolaryngology Vol. 41; no. 6; p. 102723
Main Authors: Ras, Aboubakr Elshafey, Hamed, Mona Hosny, Abdelalim, Abdelrahman Ahmed
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-11-2020
Elsevier Limited
Subjects:
Acetates - administration & dosage
Adenoid
Adenoid hypertrophy
Adenoids - pathology
Administration, Intranasal
Age
Asthma
Child
Child, Preschool
Comparative studies
Drug Therapy, Combination
Endoscopy
Evaluation
Female
Humans
Hypertrophy
Hypertrophy - drug therapy
Male
Mometasone furoate
Mometasone Furoate - administration & dosage
Montelukast
Mouth
Nasal spray
Nasal Sprays
Nose
Otolaryngology
Pediatrics
Prospective Studies
Quinolines - administration & dosage
Recurrence
Sleep apnea
Therapy
Treatment Outcome
Egypt
Montelukast
Mometasone furoate
Adenoid hypertrophy
Nasal spray
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the role of combined therapy using montelukast and intranasal mometasone furoate compared to intranasal mometasone furoate alone in treatment of adenoid hypertrophy regarding efficacy and recurrence rate. The study included 100 children with adenoid hypertrophy, they were randomly assigned to two groups. Group I (50 patients) received combined therapy using montelukast and mometasone furoate nasal spray. Group II (50 patients) received only mometasone furoate nasal spray. Patients were treated for 3 months and observed for 3 months after stoppage of treatment. Patients were evaluated using symptoms scores, Adenoid/Nasopharyngeal ratio and endoscopic grading of adenoid hypertrophy. After 3 months of treatment, group I showed significant better scores of main symptoms than group II; (P = 0.001), (P = 0.019) and (P = 0.008) for rhinorrhea, mouth breathing and snoring respectively. The mean A/N ratio was 52.8 ± 11.3 in group I better than 62.88 ± 12.10 in group II (P < 0.001). Regarding the adenoid hypertrophy grading, significant reduction in size was found in group I in 34 (68%) patients better than in group II in 18 (36%) patients (P = 0.001). After further 3 months of follow up, the mean A/N ratio was 58.46 ± 10.05 in group I better than 66.36 ± 10.46 in group II (P < 0.001). Recurrence occurred in 8 (23.5%) cases out of 34 improved cases in group I better than 10 (55.5%) cases out of 18 cases in group II (P = 0.02). Combining oral montelukast with intranasal mometasone in treatment of adenoid hypertrophy provided better improvements and less recurrence in comparison with single therapy using intranasal mometasone alone.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0196-0709
1532-818X
DOI:10.1016/j.amjoto.2020.102723